Cargando…

Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study

PURPOSE: The discrepancy between the biomarkers of disease’s activity in acromegalic patients (GH and IGF-1) is almost frequent representing a challenge for the development of comorbidities in the long term. The aim of this study was to evaluate the prevalence and severity of metabolic comorbidities...

Descripción completa

Detalles Bibliográficos
Autores principales: Romanisio, Martina, Pitino, Rosa, Ferrero, Alice, Pizzolitto, Francesca, Costelli, Samuele, Antoniotti, Valentina, Marzullo, Paolo, Aimaretti, Gianluca, Prodam, Flavia, Caputo, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565344/
https://www.ncbi.nlm.nih.gov/pubmed/37829686
http://dx.doi.org/10.3389/fendo.2023.1256975
_version_ 1785118674371215360
author Romanisio, Martina
Pitino, Rosa
Ferrero, Alice
Pizzolitto, Francesca
Costelli, Samuele
Antoniotti, Valentina
Marzullo, Paolo
Aimaretti, Gianluca
Prodam, Flavia
Caputo, Marina
author_facet Romanisio, Martina
Pitino, Rosa
Ferrero, Alice
Pizzolitto, Francesca
Costelli, Samuele
Antoniotti, Valentina
Marzullo, Paolo
Aimaretti, Gianluca
Prodam, Flavia
Caputo, Marina
author_sort Romanisio, Martina
collection PubMed
description PURPOSE: The discrepancy between the biomarkers of disease’s activity in acromegalic patients (GH and IGF-1) is almost frequent representing a challenge for the development of comorbidities in the long term. The aim of this study was to evaluate the prevalence and severity of metabolic comorbidities (diabetes, hypertension, and dyslipidemia) in surgically treated acromegalic patients with disease control and discordant GH and/or IGF-1 levels compared with those with concordant values. PATIENTS AND METHODS: Retrospective monocentric observational study on acromegalic surgically treated patients with biochemical remission (group A) or mild discordant GH or IGF-1 levels (group B). Metabolic complications and medical therapy were assessed at diagnosis and at the last follow-up visit. Severity of the disease was set for drug titration or shift to another molecule or more than before. RESULTS: There were 18 patients that met the inclusion criteria [group A: nine patients; group B: nine patients, follow-up 7 years (IQR 5.0;11.25)]. The prevalence of female patients was significantly higher in the remission group compared with the discordant group (p < 0.02). Considering metabolic complications, at the last follow-up, 61.1% was affected by hypertension, 33.3% by diabetes, and 61.1% by dyslipidemia, without differences between groups. Drug characteristics (dose, shift, number) during the follow-up did not differ significantly between groups. CONCLUSION: Metabolic complications, mainly dyslipidemia, are frequent in cured acromegalic patients, but GH/IGF-1 discrepancy does not seem to represent a risk factor for their presence or persistence. More extended studies are needed to confirm our results in a long-term period.
format Online
Article
Text
id pubmed-10565344
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105653442023-10-12 Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study Romanisio, Martina Pitino, Rosa Ferrero, Alice Pizzolitto, Francesca Costelli, Samuele Antoniotti, Valentina Marzullo, Paolo Aimaretti, Gianluca Prodam, Flavia Caputo, Marina Front Endocrinol (Lausanne) Endocrinology PURPOSE: The discrepancy between the biomarkers of disease’s activity in acromegalic patients (GH and IGF-1) is almost frequent representing a challenge for the development of comorbidities in the long term. The aim of this study was to evaluate the prevalence and severity of metabolic comorbidities (diabetes, hypertension, and dyslipidemia) in surgically treated acromegalic patients with disease control and discordant GH and/or IGF-1 levels compared with those with concordant values. PATIENTS AND METHODS: Retrospective monocentric observational study on acromegalic surgically treated patients with biochemical remission (group A) or mild discordant GH or IGF-1 levels (group B). Metabolic complications and medical therapy were assessed at diagnosis and at the last follow-up visit. Severity of the disease was set for drug titration or shift to another molecule or more than before. RESULTS: There were 18 patients that met the inclusion criteria [group A: nine patients; group B: nine patients, follow-up 7 years (IQR 5.0;11.25)]. The prevalence of female patients was significantly higher in the remission group compared with the discordant group (p < 0.02). Considering metabolic complications, at the last follow-up, 61.1% was affected by hypertension, 33.3% by diabetes, and 61.1% by dyslipidemia, without differences between groups. Drug characteristics (dose, shift, number) during the follow-up did not differ significantly between groups. CONCLUSION: Metabolic complications, mainly dyslipidemia, are frequent in cured acromegalic patients, but GH/IGF-1 discrepancy does not seem to represent a risk factor for their presence or persistence. More extended studies are needed to confirm our results in a long-term period. Frontiers Media S.A. 2023-09-27 /pmc/articles/PMC10565344/ /pubmed/37829686 http://dx.doi.org/10.3389/fendo.2023.1256975 Text en Copyright © 2023 Romanisio, Pitino, Ferrero, Pizzolitto, Costelli, Antoniotti, Marzullo, Aimaretti, Prodam and Caputo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Romanisio, Martina
Pitino, Rosa
Ferrero, Alice
Pizzolitto, Francesca
Costelli, Samuele
Antoniotti, Valentina
Marzullo, Paolo
Aimaretti, Gianluca
Prodam, Flavia
Caputo, Marina
Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
title Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
title_full Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
title_fullStr Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
title_full_unstemmed Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
title_short Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
title_sort discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565344/
https://www.ncbi.nlm.nih.gov/pubmed/37829686
http://dx.doi.org/10.3389/fendo.2023.1256975
work_keys_str_mv AT romanisiomartina discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT pitinorosa discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT ferreroalice discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT pizzolittofrancesca discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT costellisamuele discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT antoniottivalentina discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT marzullopaolo discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT aimarettigianluca discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT prodamflavia discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy
AT caputomarina discordantbiochemicalparametersofacromegalyremissiondonotinfluencetheprevalenceoraggressivenessofmetaboliccomorbiditiesasinglecenterstudy